Implementation Resources for Professionals

Clinical Pharmacogenetics at St. Jude

PG4KDS Publications

  • Gammal RS, et al. Pharmacogenetics for safe codeine use in sickle cell disease. Pediatrics. 2016;138(1):e20153479 [Epub ahead of print]. PMID: 27335380
  • Dunnenberger HM, et al. Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five United States Medical Centers. Ann Rev Pharmacol Toxicol 2015;55:89-1062014. PMID: 25292429
  • Hoffman JM, et al. PG4KDS: A model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet C Semin Med Genet. 2014;166C(1):45-55. PMID: 24619595
  • Bell GC, et al. Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc. 2014;21:e93-9 PMID: 23978487
  • Hicks JK, et al. A Clinician-Driven Automated System for Integration of Pharmacogenetic Interpretations Into an Electronic Medical Record. Clin Pharmacol Ther. 2012;92(5):563-6. PMID: 22990750
  • Crews KR, et al. Pharmacogenomics and individualized medicine: Translating science into practice. Clin Pharmacol Ther. 2012;92(4):467-75. PMID: 22948889
  • Fernandez CA, et al. Concordance of DMET Plus genotypes with orthogonal genotyping methods. Clin Pharmacol Ther. 2012 Sep;92(3):360-5. PMID: 22871999
  • Crews KR, et al. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health-Syst Pharm. 2011;68:143-50. PMID: 21200062

PG4KDS Presentations

Clinical Pharmacogenetics Implementation Consortium (CPIC™) by Mary V. Relling at the Pharmacogenomics Research Network (PGRN) 2016.

Clinical Implementation of Pharmacogenetics by Mary V. Relling at the University of Maryland 

Clinical Implementation of Pharmacogenomics Through a Pharmacist-Managed Service by Kristine R. Crews at the American Association of Colleges of Pharmacy

Integration of Pharmacogenetics into Clinical Practice by Mary V. Relling at the Cleveland Clinic

Institutional Leadership Perspective on Implementing Genomic Medicine Programs by William E. Evans at the National Human Genome Research Institute (link on NHGRI has audio too)

PG4KDS Protocol: Clinical Implementation of Preemptive Pharmacogenetics by Mary V. Relling at the American Society of Clinical Pharmacology and Therapeutics

Beyond the Hype-Developing, Implementing and Sharing Pharmacogenomic Clinical Decision Support by James M. Hoffman at the American Medical Informatics Association Annual Symposium

Pharmacogenetics Video

Clinical Pharmacogenomics: Translating Research to Patient Care by Kristine R. Crews at the University of Florida

Implementation of Preemptive Clinical Pharmacogenetics by Mary V. Relling at the Mayo Clinic Center for Individualized Medicine (Look for 2013, Day 2: Tuesday, October 1 presentations and click on Mary V. Relling)

Institutional Leadership Perspective on Implementing Genomic Medicine Programs by William E. Evans at the National Human Genome Research Institute

Putting Pharmacogenomics into Practice: Successful Implementation in Pediatrics by Kristine Crews at Cincinnati Children’s Hospital

Pharmacogenetics and Individualized Therapy by Kristine Crews at St. Jude Children’s Research Hospital (free sign in access required)

Pharmacogenetic Competencies

Introduction to pharmacogenetics competency

Cytochrome P450 2C19 (CYP2C19) competency

Cytochrome P450 2D6 (CYP2D6) competency

SLCO1B1 Pharmacogenetic competency

Thiopurine S-Methyltransferase (TPMT) competency

Dihydropyrimidine Dehydrogenase (DPYD) Competency

Uridine Diphosphate Glucuronyltransferase 1A1 (UGT1A1) competency

Residency Training in Pharmacogenetics

St. Jude offers an ASHP accredited PGY-2 residency in pharmacogenetics. Read more about the residency program.

Other Resources

The Clinical Pharmacogenetics Implementation Consortium (CPIC™) and CPIC Guidelines

  • CPIC™ is a joint effort between the PGRN and PharmGKB
  • CPIC guidelines are designed to help clinicians understand HOW available genetic test results should be used to optimize drug therapy, rather than WHETHER tests should be ordered.
  • A key assumption underlying the CPIC guidelines is that clinical high-throughput and pre-emptive (pre-prescription) genotyping will become more widespread, and that clinicians will be faced with having patients' genotypes available even if they have not explicitly ordered a test with a specific drug in mind.
  • Each guideline is published in Clinical Pharmacology and Therapeutics and on www.pharmgkb.org
  • Click here for all accepted and published guidelines
  • CPIC guidelines are also deposited on www.guidelines.gov
  • Listen to a podcast on the Clinical Pharmacogenetics Implementation Consortium (dated 03/25/14)

PharmGKB and the PGRN


If you have specific questions about implementation of clinical pharmacogenetics, you can contact the pharmacogenetics coordinator at: cyrine.haidar@stjude.org.

Legal Disclaimer: This page is intended to provide implementers with guidance on establishing a clinical pharmacogenetic program at their institution. Information contained on this page is for information and educational purposes only. Although reasonable efforts have been made to ensure that the information provided on this page is current, complete and, where appropriate, based on scientific evidence, St. Jude Children's Research Hospital makes no assurances as to whether the provided information will at all times be current or complete. St. Jude Children's Research Hospital, in offering this document, is not providing medical advice or offering a consultative opinion, and is not establishing a treatment relationship with any given individual. You, therefore, should not substitute information contained herein for your own professional judgment, nor should you rely on information provided herein in rendering a diagnosis or choosing a course of treatment for a particular individual.